Inhibiting hepatitis c virus processing and replication
OwnerLloyd Waxmaninventor
Life of this patent
Estimating the term…
Abstract
The present invention features methods for inhibiting HCV replication and processing by targeting heat shock protein 90 (HSP90). HSP90 is a cellular chaperone protein that was found to be an essential factor in NS2/3 self-cleavage. HSP90 can be targeted using compounds inhibiting the ability of HSP90 to facilitate NS2/3 cleavage.
Claims18
A method of inhibiting Hepatitis C virus (HCV) replication or processing in a cell infected with HCV comprising the step of providing to said cell an effective amount of an HSP90 inhibitor.
A method of inhibiting NS2/3 cleavage comprising the step of providing to a polypeptide comprising NS2/3 activity an effective amount of an HSP90 inhibitor.
A method of inhibiting HCV replication in a patient comprising the step of administering to said patent an effective amount of a HSP90 inhibitor.
A method of identifying a NS2/3 processing inhibitor comprising the steps of:
- a) measuring the ability of a compound to inhibit HSP90 association to a polypeptide comprising NS2/3 activity;
- and
- b) measuring the ability of said compound to inhibit NS2/3 cleavage.
A method of identifying an HCV replication inhibitor comprising the steps of:
- a) measuring the ability of a compound to inhibit HSP90 activity;
- and
- b) measuring the ability of said compound to inhibit HCV replication.
A method of identifying an HCV- replication inhibitor comprising the steps of:
- a) measuring the ability of a compound to inhibit HSP90 association to a polypeptide comprising NS2/3 activity;
- and
- b) measuring the ability of said compound to inhibit HCV replication.
Dependencies are inferred from the claim text.